BR0315934A - Mutante de herpesvìrus 5 bovino, método para preparar uma vacina, vacina, método para distinguir um ruminante infectado com uma cepa de bhv5 de tipo selvagem ou vacinado contra bhv5, e, kit de teste - Google Patents

Mutante de herpesvìrus 5 bovino, método para preparar uma vacina, vacina, método para distinguir um ruminante infectado com uma cepa de bhv5 de tipo selvagem ou vacinado contra bhv5, e, kit de teste

Info

Publication number
BR0315934A
BR0315934A BR0315934-5A BR0315934A BR0315934A BR 0315934 A BR0315934 A BR 0315934A BR 0315934 A BR0315934 A BR 0315934A BR 0315934 A BR0315934 A BR 0315934A
Authority
BR
Brazil
Prior art keywords
bhv5
vaccine
vaccinated
mutant
distinguishing
Prior art date
Application number
BR0315934-5A
Other languages
English (en)
Inventor
Franciscus Antonius Rijsewijk
Original Assignee
Id Lelystad Inst Dierhouderij
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Lelystad Inst Dierhouderij filed Critical Id Lelystad Inst Dierhouderij
Publication of BR0315934A publication Critical patent/BR0315934A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MUTANTE DE HERPESVìRUS 5 BOVINO, MéTODO PARA PREPARAR UMA VACINA, VACINA, MéTODO PARA DISTINGUIR UM RUMINANTE INFECTADO COM UMA CEPA DE BHV5 DE TIPO SELVAGEM OU VACINADO CONTRA BHV5, E, KIT DE TESTE". A invenção refere-se ao campo de encefalite em ruminantes. A invenção provê um mutante de herpesvírus 5 bovino (BHV5) provido com uma deleção funcional em cada um de pelo menos dois genes relacionados com a manifestação clínica de neurovirulência quando da infecção de um hospedeiro com BHV5. Além disso, a invenção provê uma vacina compreendendo este mutante. A invenção ainda provê um método para distinguir um ruminante infectado com uma cepa de BHV5 de tipo selvagem ou vacinado contra BHV5 em uma população de ruminantes vacinados com uma vacina de acordo com a invenção compreendendo o teste de um ruminante pela presença ou ausência de um anticorpo dirigido contra o gene de glicoproteína I (gI) ou o gene de glicoproteína E (gE) ou ambos.
BR0315934-5A 2002-11-01 2003-11-03 Mutante de herpesvìrus 5 bovino, método para preparar uma vacina, vacina, método para distinguir um ruminante infectado com uma cepa de bhv5 de tipo selvagem ou vacinado contra bhv5, e, kit de teste BR0315934A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02079559A EP1415665A3 (en) 2002-11-01 2002-11-01 BHV5 mutants
PCT/NL2003/000762 WO2004039400A2 (en) 2002-11-01 2003-11-03 Bhv5 mutants

Publications (1)

Publication Number Publication Date
BR0315934A true BR0315934A (pt) 2005-09-13

Family

ID=32088042

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0304750A BRPI0304750B1 (pt) 2002-11-01 2003-10-31 mutante de herpesvírus bovino tipo 5, vacina dirigida contra a encefalite viral bovina (bhv-5) e o vírus rábico e método de preparação da vacina
BR0315934-5A BR0315934A (pt) 2002-11-01 2003-11-03 Mutante de herpesvìrus 5 bovino, método para preparar uma vacina, vacina, método para distinguir um ruminante infectado com uma cepa de bhv5 de tipo selvagem ou vacinado contra bhv5, e, kit de teste

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0304750A BRPI0304750B1 (pt) 2002-11-01 2003-10-31 mutante de herpesvírus bovino tipo 5, vacina dirigida contra a encefalite viral bovina (bhv-5) e o vírus rábico e método de preparação da vacina

Country Status (3)

Country Link
EP (1) EP1415665A3 (pt)
BR (2) BRPI0304750B1 (pt)
WO (1) WO2004039400A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
EP2059255A4 (en) * 2006-09-08 2011-08-31 Univ Pennsylvania VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2114449B1 (en) 2006-12-28 2016-02-17 The Trustees of the University of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.

Also Published As

Publication number Publication date
WO2004039400A3 (en) 2004-11-11
BR0304750A (pt) 2004-08-31
BRPI0304750B1 (pt) 2016-10-11
EP1415665A2 (en) 2004-05-06
EP1415665A3 (en) 2004-06-30
WO2004039400A2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
Bisht et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
Collins et al. Newcastle disease virus stimulates the cellular accumulation of stress (heat shock) mRNAs and proteins
Zou et al. Construction of a highly efficient CRISPR/Cas9-mediated duck enteritis virus-based vaccine against H5N1 avian influenza virus and duck Tembusu virus infection
Fulton et al. Bovine viral diarrhea virus cytopathic and noncytopathic biotypes and type 1 and 2 genotypes in diagnostic laboratory accessions: clinical and necropsy samples from cattle
BRPI0208301B8 (pt) ácido nucléico isolado, e, composição
BRPI0512421A (pt) recombinantes de avipox expressando genes do vìrus da doença febre aftosa
Fulton et al. Bovine coronaviruses from the respiratory tract: antigenic and genetic diversity
Balinsky et al. Sheeppox virus kelch-like gene SPPV-019 affects virus virulence
Mercer et al. Molecular genetic analyses of parapoxviruses pathogenic for humans
Mumford et al. Protection against experimental infection with influenza virus A/equine/Miami/63 (H3N8) provided by inactivated whole virus vaccines containing homologous virus
Denzler et al. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques
He et al. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type
Golden et al. An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection
Julander et al. Immunogenicity and protection after vaccination with a modified vaccinia virus Ankara-vectored yellow fever vaccine in the hamster model
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
Tsukiyama et al. Development of heat-stable recombinant rinderpest vaccine
BR0315934A (pt) Mutante de herpesvìrus 5 bovino, método para preparar uma vacina, vacina, método para distinguir um ruminante infectado com uma cepa de bhv5 de tipo selvagem ou vacinado contra bhv5, e, kit de teste
DE60336927D1 (pt)
Kano et al. Cytokine profiles in chickens infected with virulent and avirulent Marek's disease viruses: Interferon‐gamma is a key factor in the protection of Marek's disease by vaccination
HUP9901005A2 (hu) Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B
Garza et al. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit model
PARIN et al. Detection of Coxiella burnetii prevalence in bovine, ovine and caprine herds
Diamond et al. Examination of gene expression in saliva samples from COVID-19 patients to study the host defense response against SARS-CoV-2 in the oral cavity
HUP0100130A2 (hu) Rekombináns Mycoplasma hyopneumoniae vakcina
Lourenço et al. Zoonotic vaccinia virus strains belonging to different genetic clades exhibit immunomodulation abilities that are proportional to their virulence

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.